Odyssey Therapeutics

[Odyssey Therapeutics @Odyssey_Tx]

Odyssey Therapeutics will participate in three upcoming global healthcare investor conferences this September. We look forward to sharing more about our work to transform the standard of care for patients with autoimmune and inflammatory diseases, progress across our pipeline, and clinical milestones ahead.
Learn more: https://t.co/QQWqrEFxbe
#Biotech #InvestorRelations $ODTX

[Odyssey Therapeutics @Odyssey_Tx]

Odyssey Therapeutics $ODTX reported its Q2 2026 financial results this morning. Read the press release here: https://t.co/hVpzMaBM2j

[Nasdaq Exchange @NasdaqExchange]

.@Odyssey_tx is on a mission to redefine the standard of care for patients suffering from autoimmune and inflammatory diseases.

See the highlights from their MarketSite milestone celebrations. #NasdaqListed $ODTX

[Nasdaq Exchange @NasdaqExchange]

.@Odyssey_tx officially joins Nasdaq, trading under $ODTX. Welcome to your next chapter. #NasdaqListed

[Odyssey Therapeutics @Odyssey_Tx]

We’re pleased to welcome H. Martin Seidel, Ph.D., CEO of IFM Therapeutics, to Odyssey’s Scientific Advisory Board. Martin will help guide our efforts to precisely target disease pathology in autoimmune and inflammatory disease. https://t.co/EvBBZGejX6

[Odyssey Therapeutics @Odyssey_Tx]

Today we welcome Jolie M. Siegel to Odyssey Therapeutics as EVP & General Counsel. With more than 20 years in biotech and life sciences, Jolie will lead legal, compliance, governance & risk as we advance our growing immunology portfolio.

Learn more: https://t.co/2lgQAsJ2pw

[Odyssey Therapeutics @Odyssey_Tx]

Today, we welcome Dennis Dean, Ph.D., as EVP and Head of Non-Clinical Development. With over 25 years of experience, Dr. Dean will lead all preclinical research and development activities that support the progression of Odyssey’s drug candidates. More: https://t.co/zeq8HQQFAi

[Odyssey Therapeutics @Odyssey_Tx]

We’re thrilled to welcome Nia Tatsis, PhD, to our Board of Directors. Her global expertise in clinical development, regulatory, and quality assurance will be invaluable as we work to deliver transformative medicines to patients in need.

Learn more: https://t.co/1cglMvyg7B

[Odyssey Therapeutics @Odyssey_Tx]

Today, we announce the closing of a $213M Series D financing round. Thank you to our investors for supporting the advancement of our portfolio of clinical and preclinical medicines designed to precisely treat the drivers of complex autoimmune diseases.

https://t.co/bzVOFBMGyF

[Odyssey Therapeutics @Odyssey_Tx]

Congrats to @ScorpionTx and Gary D. Glick, Odyssey Founder & CEO, and Scorpion Founder and founding CEO, who announced its acquisition by @EliLillyandCo, a medicine company turning science into healing to make life better for people around the world. More: https://t.co/tQiMyKupTJ

[Odyssey Therapeutics @Odyssey_Tx]

Meet #EmployeeSpotlight Dominik Kölmel. Approaching three years at Odyssey, Dominik was drawn to our commitment to bringing next-generation precision medicines to patients in need. Beyond work, he’s a world traveler and his favorite experience was a memorable trip to Hawaii. 🌍

[Odyssey Therapeutics @Odyssey_Tx]

Ryan began as an intern pursuing his passion for #MachineLearning. Now full-time, he explores innovative research practices, challenging implementation & engineering problems, & new types of science. Outside work, Ryan loves running & studying languages. 🌍🏃‍♂️ #EmployeeSpotlight

[Odyssey Therapeutics @Odyssey_Tx]

Odyssey is pleased to introduce William Roush, Ph.D., as EVP and Head of Small Molecule Research. Dr. Roush will oversee the prosecution of Odyssey’s small molecule, preclinical portfolio from target selection into early development. Read more: https://t.co/NcHlsgETxv

[Odyssey Therapeutics @Odyssey_Tx]

#EmployeeSpotlight 🌟 Dai Tianero-McIntosh joined #TeamOdyssey nearly 3yrs ago to learn from industry leaders in drug discovery and loves collaborating with diverse colleagues. Outside work, she explores Boston and New England with her family, enjoying beaches 🏖️ and gardens 🌺.

[Odyssey Therapeutics @Odyssey_Tx]

Our next #EmployeeSpotlight features Jim Ferrucci, Corporate Controller. Jim joined #TeamOdyssey last year to learn about the fascinating science behind drug discovery and believes in our team's passion and commitment. He enjoys spending time with his family, 🏒, 🎣, and 🏌️‍♂️

[Odyssey Therapeutics @Odyssey_Tx]

#EmployeeSpotlight Laura Preiss joined us 2.5 years ago, drawn by the excellent science and outstanding team. Outside work, she enjoys memorable experiences like road trips through Florida, finds inspiration in Yotam Ottolenghi's cookbooks, and indulges in caring for her orchids.

[Odyssey Therapeutics @Odyssey_Tx]

Yesterday, our Chief Data Officer Joe McDonald joined industry leaders for a panel discussion on the opportunities and challenges of using AI and ML tools for identification and optimization of therapeutic molecules. Thank you, @IAmBiotech, for hosting us! #BIO2024

[Odyssey Therapeutics @Odyssey_Tx]

[2/2] Joe will join a panel again tomorrow from 11:00 a.m. to 12:00 p.m. PT in section 30ABC titled: “Using AI/ML for Identification and Optimization of Therapeutic Molecules.” We encourage those attending #BIO2024 to stop by and listen in.

[Odyssey Therapeutics @Odyssey_Tx]

[1/2] Today, our Chief Data Officer Joe McDonald participated in a #BIO2024 panel discussion, highlighting the power of #AI and #ML in drug discovery, emphasizing scientists' crucial role in interpreting and utilizing these insights.

[Odyssey Therapeutics @Odyssey_Tx]

Our Chief Data Officer, Dr. Joe McDonald, will join other experts in two panel sessions at #BIO2024 on the topics of #AI and #MachineLearning in R&D and for identification and optimization of therapeutic models. 🎤 More on each panel: https://t.co/FsoLNvJo06